Moleculin Biotechnology

Board of Director

August 16, 2022

Public, Clinical Stage, Pharmaceutical company sought to expand their Board of Directors

Moleculin Biotech, Inc. is a public clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of highly resistant tumors and viruses. The company’s lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.

With a need to add to thir growing board, they wanted someone with strong clinical development experience with a history of working well with existing long term board members to improve outcomes. The ideal profile would need to have a strong personality, a background in clinical development, and be a great culture fit for their tight knit board.

The Approach

The search process went smoothly with great interest from candidates because of Moleculin’s strong management team and board reputation.

  • We looked at East Coast markets with prior experience working in clinical development in public companies focused in Oncology.
  • LifeSci Search worked to develop an attractive story for the company, their board, and management team that helped lead to our placement of Joy Yan, MD, PhD, their newest board member

The Outcome

LifeSci Search identified and placed Joy Yan, MD, PhD as BOD for Moleculin. Joy’s background was what they were looking for. She is well respected with a great reputation in the market, and has experience at public clinical development & oncology companies.

Search Data

Mapped Candidates  16
Candidates Formally Presented: 6
Time to Hire 4 months


Joy Yan, MD, PhD | BOD

  • CMO, KeyMed Biosciences
  • CMO & SAB, Ambryx
  • Senior Clinical Lead, Team Leader, Immuno-Oncology, Bristol-Myers Squibb

Ready to realize your future?